- Home
- IFRX vs ZENV Comparison
IFRX vs ZENV Comparison
Compare IFRX & ZENV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- ZENV
- Stock Information
- Founded
- IFRX 2007
- ZENV 2005
- Country
- IFRX Germany
- ZENV Brazil
- Employees
- IFRX N/A
- ZENV N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- ZENV Computer Software: Prepackaged Software
- Sector
- IFRX Health Care
- ZENV Technology
- Exchange
- IFRX Nasdaq
- ZENV Nasdaq
- Market Cap
- IFRX 65.8M
- ZENV 65.5M
- IPO Year
- IFRX 2017
- ZENV 2021
- Fundamental
- Price
- IFRX $0.78
- ZENV $1.45
- Analyst Decision
- IFRX Strong Buy
- ZENV
- Analyst Count
- IFRX 4
- ZENV 0
- Target Price
- IFRX $7.75
- ZENV N/A
- AVG Volume (30 Days)
- IFRX 850.4K
- ZENV 100.5K
- Earning Date
- IFRX 08-07-2025
- ZENV 07-14-2025
- Dividend Yield
- IFRX N/A
- ZENV N/A
- EPS Growth
- IFRX N/A
- ZENV N/A
- EPS
- IFRX N/A
- ZENV N/A
- Revenue
- IFRX $140,242.00
- ZENV $155,164,999.00
- Revenue This Year
- IFRX $3.36
- ZENV $8.58
- Revenue Next Year
- IFRX $100.60
- ZENV $8.83
- P/E Ratio
- IFRX N/A
- ZENV N/A
- Revenue Growth
- IFRX 30.90
- ZENV 18.83
- 52 Week Low
- IFRX $0.71
- ZENV $1.02
- 52 Week High
- IFRX $2.82
- ZENV $3.30
- Technical
- Relative Strength Index (RSI)
- IFRX 33.05
- ZENV 52.70
- Support Level
- IFRX $0.81
- ZENV $1.21
- Resistance Level
- IFRX $0.86
- ZENV $1.57
- Average True Range (ATR)
- IFRX 0.06
- ZENV 0.10
- MACD
- IFRX -0.03
- ZENV 0.03
- Stochastic Oscillator
- IFRX 6.14
- ZENV 67.57
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.